Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexstim OyjFRA:5NX +6.07%69 Shareholder Yield % is -4.99% as of Jun. 2026. GuruFocus rates FRA:5NX with a GF Score™ of 69/100 and a GF Value™ of €9.65 (Fairly Valued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Nexstim Oyj ranks worse than 73.99% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Nexstim Oyj's Shareholder Yield % was -4.99%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Nexstim Oyj Shareholder Yield % Related Terms
Nexstim Oyj Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Nexstim Oyj's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5NX vs ABT, SYK, MDT: Shareholder Yield % Comparison
For the Medical Devices subindustry, Nexstim Oyj's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj Shareholder Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Nexstim Oyj (FRA:5NX) has a Shareholder Yield % of -4.99% as of Jun. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Nexstim Oyj and its competitors. According to the industry distribution chart, Nexstim Oyj ranks #603 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 74%.
Is Nexstim Oyj's Shareholder Yield % too high?
Nexstim Oyj's current Shareholder Yield % is -4.99%. Based on the distribution chart, Nexstim Oyj ranks #603 out of 815 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nexstim Oyj has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's Shareholder Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nexstim Oyj ranks #603 out of 815 companies for Shareholder Yield %. This places Nexstim Oyj in the lower half of its industry. The industry median Shareholder Yield % is 0.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Devices & Instruments company?
The median Shareholder Yield % among Medical Devices & Instruments companies is 0.25, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Nexstim Oyj and its competitors. For the Medical Devices & Instruments industry, the median Shareholder Yield % is 0.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexstim Oyj's current Shareholder Yield % is -4.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (FRA:5NX) is currently considered Fairly Valued. The stock's GF Value™ is €9.65, compared to a current price of €9.78 — trading 1.3% above its estimated fair value. The current Shareholder Yield % is -4.99%. Nexstim Oyj's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Nexstim Oyj (FRA:5NX), the current Shareholder Yield % is -4.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (FRA:5NX) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €9.78 is trading 1.3% above its estimated GF Value™ of €9.65.
GuruFocus considers Nexstim Oyj to be Fairly Valued.
Key valuation signals for FRA:5NX:
Shareholder Yield %: -4.99%
GF Value™: €9.65 vs. price of €9.78 (1.3% above fair value)
No single metric tells the full story. See the FRA:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
69GF Score
Get the complete analysis for FRA:5NX
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5NX has been successfully added to your 
